PRV211
AssetAlso PRV211 (Intraoperative Cisplatin System)
Intraoperative local cisplatin delivery inducing DNA crosslinks and tumor cell death
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- DNA damage response
- 1
- Indication
- 2,008
- Trials
- 1
- Developer
Indications
1Oral squamous cell carcinoma
Phase 2, Recruiting, NCT05893888, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains3
- Owner and partners1
- Trials2,008
- Evidence for its targets3
- Competitors12
Every asset’s record: target, stage, trials and the evidence behind it.